In this work, we examined the structural features of SMYD3 that interact favorably with Inhibitor-4, and also assessed its effects on colorectal and lung cancer cell lines, which, along with breast cancer lines, have been shown to overexpress SMYD3. Here, SMYD3 is linked to breast carcinoma.